Curis Inc (CRIS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.60
- As of
Kresmion compiles this page from CRIS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
CURIS INC (CRIS): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-14.
See the full CRIS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CRIS on one page. Preview it with sample data, then open it live with a free account.
Preview the CRIS dossierActive signals for CRIS
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 49.7%, EPS $-4.02 vs $-7.9968 estimate
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 61% of CRIS (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +52% to CRIS (2026Q1)
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 8.9% - EPS $-10 vs $-9.18 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 206.4% - EPS $-25 vs $-8.16 estimate
FREE, NO ACCOUNT
Every signal on CRIS, as it fires
You are seeing 5 of 11 signals recorded on CRIS since 2026-05-26.
The five above landed across 4 days. The other 6 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CRIS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 231269309 · 2026Q2 | $74K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CRIS
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
CRIS against its peers
CRIS's return on equity of -138.8% ranks in the 50th percentile of 8 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | CRIS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 9.4M USD | 658000 USD | 79 | 6 |
| Operating margin | -60.5% | n/a | n/a | 4 |
| Net margin | -80.3% | n/a | n/a | 4 |
| Return on equity | -138.8% | -156.4% | 50 | 8 |
| 1 year | -98.1% | -91.0% | 13 | 11 |
Peers (15): ARTL, VBIO, TCRT, BCAB, OGEN, SCNI, GNPX, ISCO, CASIF, VSBC, ABPO, SLXN, PPBT, ACUT, PTIX. Left out: LABT (no annual filing), AGNPD (no annual filing), GPLL (period gap), ELAB (no annual filing), BIXT (no annual filing), VRAX (period gap), LSBCF (period gap), BBLG (no annual filing), VCNX (period gap), CLSDQ (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (CRIS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CRIS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CRIS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.